20 patents
Utility
Pyrazole compounds and preparation thereof
16 Jan 24
Sunil Sharma, Dinesh Jangid, Priyanka Dhaka, Siddharth Madhwal, Bharat Kumar, Kapil Kumar, Rajdeep Anand, Anurag Jain
Filed: 1 Feb 19
Utility
Methods of Administering Myosin Inhibitors
26 Oct 23
Methods of administering a myosin inhibitor to a patient and related methods of risk mitigation including controls on distribution are described herein.
Vidya V. PERERA, Samira MERALI, Amy SEHNERT, Michael CHEUNG, Dewey SETO, Jeffrey LOCKMAN, Marie-Laure PAPI
Filed: 25 Apr 23
Utility
Treatment of Atrial Dysfunction
27 Jul 23
Provided herein are methods, uses, and compositions for treating AF in a patient, such as a patient exhibiting heart failure with reduced ejection fraction.
Jean-Francois TAMBY, Jay M. EDELBERG, Gregory Howard Takeo KURIO, Cynthia Lyle KELLY, Chun YANG, Marcus Patrick HENZE, Carlos L. DEL RIO, Robert Lee ANDERSON, Marius P. SUMANDEA, Jitendra GANJU
Filed: 14 Jun 21
Utility
Methods of Treatment with Myosin Modulator
25 May 23
Disclosed herein are methods of treatment comprising administering a therapeutically effective amount of a myosin modulator or a pharmaceutically acceptable salt thereof to a subject in need thereof and diagnostic methods useful in connection with those treatments.
Timothy Carlson, Carlos L. Del Rio, Jay M. Edelberg, Sarah Fernandes, Marcus Patrick Henze, Yanfei Ma, Robert McDowell, Matthew Edwards Mealiffe, Amy Sehnert, Marc J. Semigran, Kathy L. Lampl, David Zhang, Milind Y. Desai, Steve E. Nissen, Liang Fang, Joseph Lambing, Wanying Li, Danielle L. Aubele, Brian Edmund Kane, Louis Charles Sehl
Filed: 10 Nov 20
Utility
Substituted 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES for Treating Cardiac Diseases
27 Oct 22
The present disclosure provides novel tetrahydropyran (THP)-substituted bicyclic pyrimidinedione compounds that are useful for the treatment of hypertrophic cardiomyopathy (HCM), conditions associated with left ventricular hypertrophy, conditions associated with diastolic dysfunction, and/or symptoms associated thereof.
Mark Grillo, Brian Kane, Johan Oslob, Min Zhong, Fabienne Thompson
Filed: 30 Jun 22
Utility
Treatment of HCM with Pyrimidinedione Compounds
6 Oct 22
Provided are methods for treating hypertrophic cardiomyopathy and diastolic dysfunction.
Marc J. Semigran, June H. Lee, Joseph Lambing, Eric Green, Marc Evanchik, Timothy Carlson, David Zhang
Filed: 16 Jun 22
Utility
Polymorphic Forms of (R)-4-(1-((3-(DIFLUOROMETHYL)-1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-1-FLUOROETHYL)-N-(ISOXAZOL-3-YL)PIPERIDINE-1-CARBOXAMIDE
15 Sep 22
Min Zhong, Olivier Monnier, Jean-Philippe Jelin, Richard Duvoux, Jean Alie, Philippe Ochsenbein
Filed: 23 Feb 22
Utility
Treatment of Systolic Dysfunction and Heart Failure with Reduced Ejection Fraction with the Compound (R)-4-(1-((3-(DIFLUOROMETHYL)-1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-1-FLUOROETHYL)-N-(ISOXAZOL-3-YL)PIPERIDINE-1-CARBOXAMIDE
25 Aug 22
Provided herein are methods, use, and compositions for treating systolic dysfunction such as heart failure with reduced ejection fraction.
Jean-Francois Tamby, Chun Yang, Timothy Carlson
Filed: 18 May 20
Utility
Treatment of HCM with Pyrimidinedione Compounds
21 Jul 22
Provided are methods for treating hypertrophic cardiomyopathy and diastolic dysfunction.
Marc J. Semigran, June H. Lee, Joseph Lambing, Eric Green, Marc Evanchik, Timothy Carlson, David Zhang
Filed: 23 Mar 22
Utility
4-METHYLSULFONYL-SUBSTITUTED Piperidine Urea Compounds
21 Apr 22
The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve.
Johan Oslob, Danielle Aubele, Jae Kim, Robert McDowell, Yonghong Song, Arvinder Sran, Min Zhong
Filed: 20 Aug 21
Utility
Pyrimidinedione Compounds
11 Nov 21
Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction.
Johan Oslob, Robert Anderson, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Brian Kane, Puping Lu, Robert McDowell, Hector Rodriguez, Yonghong Song, Arvinder Sran
Filed: 13 Jan 21
Utility
4-methylsulfonyl-substituted piperidine urea compounds
21 Sep 21
The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve.
Johan Oslob, Danielle Aubele, Jae Kim, Robert McDowell, Yonghong Song, Arvinder Sran, Min Zhong
Filed: 21 Jul 20
Utility
Substituted 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4-diones for treating cardiac diseases
15 Jun 21
Mark Grillo, Brian Kane, Johan Oslob, Min Zhong, Fabienne Thompson
Filed: 28 Oct 19
Utility
Polymorphic Forms of (R)-4-(1-((3-(DIFLUOROMETHYL)-1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-1-FLUOROETHYL)-N-(ISOXAZOL-3-YL)PIPERIDINE-1-CARBOXAMIDE
25 Feb 21
Min Zhong, Olivier Monnier, Jean-Philippe Jelin, Richard Duvoux, Jean AliƩ, Philippe Ochsenbein
Filed: 15 Jul 20
Utility
4-Methylsulfonyl-Substituted Piperidine Urea Compounds
4 Nov 20
The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve.
Johan Oslob, Danielle Aubele, Jae Kim, Robert McDowell, Yonghong Song, Arvinder Sran, Min Zhong
Filed: 20 Jul 20
Utility
Pyrimidinedione Compounds
23 Sep 20
Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction.
Johan Oslob, Robert Anderson, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Brian Kane, Puping Lu, Robert McDowell, Hector Rodriguez, Yonghong Song, Arvinder Sran
Filed: 4 Jun 20
Utility
4-methylsulfonyl-substituted piperidine urea compounds
31 Aug 20
The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve.
Johan Oslob, Danielle Aubele, Jae Kim, Robert McDowell, Yonghong Song, Arvinder Sran, Min Zhong
Filed: 1 Oct 18
Utility
Tetrahydropyran (Thp)-substituted Bicyclic-pyrimidinedione Compounds
27 May 20
The present disclosure provides novel tetrahydropyran (THP)-substituted bicyclic pyrimidinedione compounds that are useful for the treatment of hypertrophic cardiomyopathy (HCM), conditions associated with left ventricular hypertrophy, conditions associated with diastolic dysfunction, and/or symptoms associated thereof.
Mark Grillo, Brian Kane, Johan Oslob, Min Zhong, Fabienne Thompson
Filed: 27 Oct 19
Utility
Corrected4-METHYLSULFONYL-SUBSTITUTED Piperidine Urea Compounds
15 Apr 20
The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve.
Johan Oslob, Danielle Aubele, Jae Kim, Robert McDowell, Yonghong Song, Arvinder Sran, Min Zhong
Filed: 1 Oct 18
Utility
Treatment of HCM with Pyrimidinedione Compounds
19 Feb 20
Provided are methods for treating hypertrophic cardiomyopathy and diastolic dysfunction.
Marc J. Semigran, June H. Lee, Joseph Lambing, Eric Green, Marc Evanchik
Filed: 25 Mar 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first